

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Equip T suspension for injection

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each 2 ml dose contains:

Active substance:

Immunopurified Tetanus Toxoid

≥ 30 IU/ml*

*IU: International units

Adjuvant:

Aluminium phosphate

Excipients:

Qualitative composition of excipients and other constituents
Aluminium phosphate
Phosphate buffered saline

Clear liquid suspension above a whitish/grey sediment which resuspends readily on shaking.

3. CLINICAL INFORMATION

3.1 Target species

Horses.

3.2 Indications for use for each target species

For the active immunisation of horses of 5 months of age or older against tetanus to prevent mortality.

Onset of immunity: within 2 weeks of completion of the primary course.

Duration of immunity: 3 years.

3.3 Contraindications

None.

3.4 Special warnings

Vaccinate healthy animals only.

3.5 Special precautions for use

Special precautions for safe use in the target species:

The efficacy of active immunisation of young foals against equine influenza will be influenced by the level of maternally derived antibodies. This will vary between individuals due to a number of factors, e.g. the immune status of the dam; adequacy of colostral intake by the foal etc. The vaccine should not be used in foals below 5 months of

age, and foals should not be vaccinated until maternally derived antibodies have fallen below protective levels.

In any animal population there may be a small number of individuals which fail to respond fully to vaccination. Successful vaccination depends upon correct storage and administration of the vaccine and the ability of the animal to respond. This can be influenced by such factors as genetic constitution, intercurrent infection, age, nutritional status, concurrent drug therapy and stress.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

The veterinary medicinal product should be administered by respecting appropriate (aseptic) injection technique.

In case of accidental self-administration, seek medical advice immediately and show the package leaflet or the label to the physician.

Special precautions for the protection of the environment:

Not applicable.

3.6 Adverse events

Horses:

Rare (1 to 10 animals / 10,000 animals treated):	Injection site swelling ^{1,3} Stiffness ¹ Elevated temperature ^{1, 2}
Very rare (<1 animal / 10,000 animals treated, including isolated reports):	Injection site pain Hypersensitivity reaction (Anaphylactic type-reaction) ⁴

¹ This condition normally resolves by the day following vaccination.

² Mild, transient, typically 9-12 hours post vaccination.

³ Soft and non-painful measuring 10-20 mm in diameter.

⁴ Immediate treatment should be given with a soluble glucocorticoid intravenously or adrenalin intramuscularly.

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or the national competent authority via the national reporting system. See the package leaflet for respective contact details.

3.7 Use during pregnancy, lactation or lay

Pregnancy:

Can be used in pregnant mares which have been vaccinated against tetanus before pregnancy.

Heavily pregnant mares should not be subject to undue stress when vaccinated.

3.8 Interaction with other medicinal products and other forms of interaction

No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.

3.9 Administration routes and dosage

Intramuscular use.

Dose: 2 ml

Administration: The veterinary medicinal product should be shaken thoroughly before use and administered by deep intramuscular injection.

Primary vaccination

Two injections of 2 ml with an interval of 4-6 weeks between them.

Booster vaccination

One dose 36 months after the primary course, repeated at intervals of up to 36 months.

3.10 Symptoms of overdose (and where applicable, emergency procedures and antidotes)

Accidental overdose is unlikely to cause any reactions other than those described in section 3.6.

3.11 Special restrictions for use and special conditions for use, including restrictions on the use of antimicrobial and antiparasitic veterinary medicinal products in order to limit the risk of development of resistance

Not applicable.

3.12 Withdrawal periods

Meat and offal: zero days.

Not authorised for use in animals producing milk for human consumption.

4. IMMUNOLOGICAL INFORMATION

4.1 ATCvet code: QI05AB03

The veterinary medicinal product stimulates active immunity against tetanus.

5. PHARMACEUTICAL PARTICULARS

5.1 Major incompatibilities

Do not mix with any other veterinary medicinal product.

5.2 Shelf life

Shelf life of the veterinary medicinal product as packaged for sale: 3 years.

5.3 Special precautions for storage

Store in a refrigerator (2 °C – 8 °C).

Protect from light.

Do not freeze.

Keep the container in the outer carton.

5.4 Nature and composition of immediate packaging

Type I glass vial with chlorobutyl rubber stopper and aluminium overseal.

Packaging: Box of 10 single dose vials. Each box contains 10 sterile disposable 2 ml syringes and 10 sterile needles.

Type I glass syringe closed with bromobutyl rubber plunger stopper and tip cap.

Packaging: Box of 10 single dose prefilled syringes with needles.

Not all pack sizes may be marketed.

5.5 Special precautions for the disposal of unused veterinary medicinal products or waste materials derived from the use of such products

Medicines should not be disposed of via wastewater or household waste.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any national collection systems applicable to the veterinary medicinal product concerned.

6. NAME OF THE MARKETING AUTHORISATION HOLDER

Zoetis Belgium S.A.

7. MARKETING AUTHORISATION NUMBER(S)

VPA10387/032/001

8. DATE OF FIRST AUTHORISATION

04/07/2014

9. DATE OF THE LAST REVISION OF THE SUMMARY OF THE PRODUCT CHARACTERISTICS

22/07/2025

10. CLASSIFICATION OF VETERINARY MEDICINAL PRODUCTS

Veterinary medicinal product subject to prescription.

Detailed information on this veterinary medicinal product is available in the [Union Product Database \(https://medicines.health.europa.eu/veterinary\)](https://medicines.health.europa.eu/veterinary).

